Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 978,582
  • Shares Outstanding, K 79,754
  • Annual Sales, $ 0 K
  • Annual Income, $ -165,790 K
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.45
Trade SRRK with:

Options Overview Details

View History
  • Implied Volatility 130.36% ( +48.37%)
  • Historical Volatility 61.60%
  • IV Percentile 89%
  • IV Rank 66.94%
  • IV High 172.09% on 11/06/23
  • IV Low 45.85% on 06/30/23
  • Put/Call Vol Ratio 2.86
  • Today's Volume 27
  • Volume Avg (30-Day) 146
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 1,505
  • Open Int (30-Day) 4,706

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.59
  • Number of Estimates 8
  • High Estimate -0.48
  • Low Estimate -0.72
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -25.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.65 +0.52%
on 05/22/24
15.82 -26.00%
on 05/03/24
-2.29 (-16.36%)
since 04/22/24
3-Month
11.65 +0.52%
on 05/22/24
17.90 -34.58%
on 03/28/24
-3.92 (-25.08%)
since 02/22/24
52-Week
5.56 +110.61%
on 05/31/23
21.17 -44.69%
on 12/28/23
+4.22 (+56.34%)
since 05/22/23

Most Recent Stories

More News
S&P 500 Posts a Record High on Optimism the Fed Can Achieve a Soft Landing

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. Stock indexes...

$SPX : 5,307.01 (-0.27%)
SPY : 529.83 (-0.29%)
$DOWI : 39,671.04 (-0.51%)
DIA : 396.66 (-0.53%)
$IUXX : 18,705.20 (-0.05%)
QQQ : 455.71 (-0.02%)
ZNM24 : 109-020 (-0.16%)
EL : 130.77 (-1.47%)
WBA : 16.47 (-1.26%)
RH : 254.31 (-7.20%)
SRRK : 11.71 (-4.56%)
APA : 30.13 (-1.92%)
Stocks Pressured by Hawkish Statement by a Fed Official

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. Stock indexes this...

$SPX : 5,307.01 (-0.27%)
SPY : 529.83 (-0.29%)
$DOWI : 39,671.04 (-0.51%)
DIA : 396.66 (-0.53%)
$IUXX : 18,705.20 (-0.05%)
QQQ : 455.71 (-0.02%)
ZNM24 : 109-020 (-0.16%)
EL : 130.77 (-1.47%)
RH : 254.31 (-7.20%)
OMC : 95.26 (+0.31%)
KMB : 133.87 (+0.10%)
W : 62.58 (-2.58%)
Stocks See Support from Improved Soft-Landing Prospects

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.08%. Stock indexes this morning...

$SPX : 5,307.01 (-0.27%)
SPY : 529.83 (-0.29%)
$DOWI : 39,671.04 (-0.51%)
DIA : 396.66 (-0.53%)
$IUXX : 18,705.20 (-0.05%)
QQQ : 455.71 (-0.02%)
ZNM24 : 109-020 (-0.16%)
EL : 130.77 (-1.47%)
RH : 254.31 (-7.20%)
SNOW : 163.34 (+0.39%)
WBA : 16.47 (-1.26%)
OMC : 95.26 (+0.31%)
Why Scholar Rock Holding Stock Soared Today

The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.

SRRK : 11.71 (-4.56%)
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today it...

SRRK : 11.71 (-4.56%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role,...

SRRK : 11.71 (-4.56%)
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that...

SRRK : 11.71 (-4.56%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role,...

SRRK : 11.71 (-4.56%)
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial...

SRRK : 11.71 (-4.56%)
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it...

SRRK : 11.71 (-4.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 13.53
2nd Resistance Point 13.17
1st Resistance Point 12.72
Last Price 11.71
1st Support Level 11.91
2nd Support Level 11.55
3rd Support Level 11.10

See More

52-Week High 21.17
Fibonacci 61.8% 15.21
Fibonacci 50% 13.36
Last Price 11.71
Fibonacci 38.2% 11.52
52-Week Low 5.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar